APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Aug. 2004, p. 4720–47260099-2240/04/$08.00ϩ0 DOI: 10.1128/AEM.70.8.4720–4726.2004Copyright © 2004, American Society for Microbiology. All Rights Reserved. Benzene-Toluene-Ethylbenzene-Xylene–EthanolMarcio L. B. Da Silva and Pedro J. J. Alvarez* Department of Civil and Environmental Engineering, University of Iowa, Iowa City, Iowa 52242 Received
Biomarker associations - osteoporosisDisease Report
Table of Contents
Reduction of bone mass without alteration in the composition of bone, leading to fractures. primary osteoporosis can be of two major types: postmenopausalosteoporosis (osteoporosis, postmenopausal) and age-related or senile osteoporosis.
Post-Traumatic Osteoporosis; Age-Related Bone Loss; Age-Related Osteoporosis; Senile Osteoporosis Biomarker Associations
Biomarkers associated with Osteoporosis (53 biomarkers)
Type of Association
Type of Indication
First Previous 1 2 3 4 5 Next Last
Retrieve Osteoporosis biomarkers for analysis
https://portal.biobase-international.com/cgi-bin/build_ghptywl/idb/1.0/pageview.cgi?view=DiseaseReport&disease_acc=DI000009558[10/1/2013 1:24:08 PM] Retrieve Osteoporosis biomarkers for export or for viewing in the BKL Pathfinder: Biomarkers with a disease relationship of Biomarkers with affected molecule type of Note: Results are returned in the BioKnowledge Search window Clinical Trials
Drugs under clinical trial investigation for treatment of Osteoporosis (358 trials)
Bone Loss in Premenopausal Women With Depression Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Completed Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Completed Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Completed Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Completed First Previous 1 2 3 4 5 Next Last
https://portal.biobase-international.com/cgi-bin/build_ghptywl/idb/1.0/pageview.cgi?view=DiseaseReport&disease_acc=DI000009558[10/1/2013 1:24:08 PM] Subtypes or forms of Osteoporosis
idiopathic; familial; more severe; early onset Biological processes affected by Osteoporosis
collagen fibril organization; bone mineralization; skeletal system development; bone remodeling; regulation of bone remodeling . Cell types or tissues affected by Osteoporosis
serum; osteoblasts; bone; mesenchyme/mesenchymal cells; monocytes Diseases associated with Osteoporosis
Spinal Fractures; beta-Thalassemia; Genetic Predisposition to Disease; Fractures, Bone; Celiac Disease . Mouse Models
Mouse genes which provide a model for Osteoporosis when knocked out
[C-abl oncogene 1 non-receptor tyrosine kinase, a Ras GTPase activator that acts in NF-kB cascade, G2-M checkpoint, antiapoptosis, B-cell differentiation, and cell migration; human ABL1 is associated with leukemias and lymphomas [Amphiregulin, a growth factor that mediates EGFR pathway, DNA replication, oocyte maturation, and antiapoptosis, acts in plasminogen activation and wound healing; human AREG is associated with asthma, HIV infection, psoriasis, myeloma, and several cancers [Beta 2-microglobulin, acts in antigen processing and presentation, mating behavior, and chemotaxis, regulates IL-2 production; human B2M is associated with AIDS, Crohn Disease, Hemophilia A and B, nervous and digestive system diseases, and several cancers [Biglycan, a structural constituent of the extracellular matrix that acts in collagen fibrillogenesis and muscle contraction; human BGN is associated with muscular dystrophy, Alzheimer disease, systemic lupus erythematosus, and coronary artery disease [Bone morphogenetic protein 3, a receptor binding protein that acts in cell-cell signaling, myeloid cell differentiation, organ morphogenesis, and skeletal development; human BMP3 is upregulated in myeloid metaplasia First Previous 1 2 3 4 Next Last
https://portal.biobase-international.com/cgi-bin/build_ghptywl/idb/1.0/pageview.cgi?view=DiseaseReport&disease_acc=DI000009558[10/1/2013 1:24:08 PM] Identifiers
BIOBASE accession : DI000009558
Jin, H. S., Kim, B. Y., Kim, J., Hong, K. W., Jung, S. Y., Lee, Y. S., Huh, D., Oh, B., Chung, Y. S., Jeong, S. Y., Association between theSPRY1 gene polymorphism and obesity-related traits and osteoporosis in Korean women. Mol Genet Metab 108 (1) 95-101 (2013).
Zhang, J. F., Fu, W. M., He, M. L., Wang, H., Wang, W. M., Yu, S. C., Bian, X. W., Zhou, J., Lin, M. C., Lu, G., Poon, W. S., Kung, H. F.,MiR-637 maintains the balance between adipocytes and osteoblasts by directly targeting Osterix. Mol Biol Cell 22 (21) 3955-61 (2011).
Valenti, M. T., Garbin, U., Pasini, A., Zanatta, M., Stranieri, C., Manfro, S., Zucal, C., Dalle Carbonare, L., Role of ox-PAPCs in thedifferentiation of mesenchymal stem cells (MSCs) and Runx2 and PPARgamma2 expression in MSCs-like of osteoporotic patients. PLoSONE 6 (6) e20363 (2011). Mendes, A. I., Mascarenhas, M. R., Matos, S., Sousa, I., Ferreira, J., Barbosa, A. P., Bicho, M., Jordan, P., A WNK4 gene variant relatesto osteoporosis and not to hypertension in the Portuguese population. Mol Genet Metab 102 (4) 465-9 (2011). Chew, S., Mullin, B. H., Lewis, J. R., Spector, T. D., Prince, R. L., Wilson, S. G., Homozygous deletion of the UGT2B17 gene is notassociated with osteoporosis risk in elderly Caucasian women. Osteoporos Int 22 (6) 1981-6 (2011). First Previous 1 2 3 4 5 Next Last
All rights reserved. Not for distribution.
https://portal.biobase-international.com/cgi-bin/build_ghptywl/idb/1.0/pageview.cgi?view=DiseaseReport&disease_acc=DI000009558[10/1/2013 1:24:08 PM]
DOCUMENTOS Código de Ética Farmacéutica y Deontología de la Profesión Farmacéutica Elaborado por la Comisión del Código Deontológico del Consejo General de Colegio Oﬁ ciales de Farmacéuticos de España. El documento fue aprobado el 14 de diciembre de 2001 por la Asamblea General de Colegios. Ahora bien, esta norma deontológica no tiene fuerza legal puesto que, aunque ya ﬁ gura